Survival Outcomes Associated with First-Line PCV or Temozolomide in Combination with Radiotherapy in IDH-mutant 1P/19q-Codeleted Grade 3 Oligodendroglioma.
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined